Buy & Sell Incyte Corporation (INCY) – Incyte Corporation Price Today
Aura AI Summary
Key Stats
- $19.09BMarket Cap
- HealthSector
- -8.66%3M Drawdown
- $15.11BEnterprise Value
- -Dividend Yield
- 33 daysTypical Hold Time
Incyte Corporation (INCY) is currently valued at a market capitalization of $19.09B, with an enterprise value of $15.11B. Over the past 52 weeks, Incyte Corporation has traded between a low of $65.31 and a high of $110.57, highlighting its annual price range. Over the past three months, Incyte Corporation has recorded a drawdown of -8.66%, reflecting recent price volatility. On average, investors hold Incyte Corporation for approximately 33 days, indicating typical investor behavior on the platform.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Most Recent News
Robbins LLP investigates Beta Bionics' executives for possible securities law violations after stock plunge.
Robbins LLP is investigating Beta Bionics, Inc.'s officers and directors for potential violations of securities laws and breaches of fiduciary duties following the company's announcement of weaker-than-expected patient growth. Beta Bionics reported a...

Robbins LLP investigates Simulation Plus officers for possible securities law violations after stock plunge.
Robbins LLP is investigating whether officers and directors of Simulation Plus, Inc. violated securities laws and breached fiduciary duties following significant stock price drops in 2025. The company faced a 24% stock decline after lowering revenue ...

Shake Shack shares plunge over 10% after cutting 2026 revenue and profit forecasts.
Shake Shack's stock dropped more than 10% after the company lowered its full-year 2026 revenue, margin, and EBITDA guidance due to macroeconomic uncertainty, competitive pressures, rising beef costs, and weak sales from weather impacts. The company r...
